APELLIS PHARMACEUTICALS INC's ticker is APLS and the CUSIP is 03753U106. A total of 262 filers reported holding APELLIS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.39 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,404,991 | +4.3% | 352,392 | +149.8% | 0.00% | 0.0% |
| Q2 2023 | $12,852,172 | +144.6% | 141,078 | +77.1% | 0.00% | +100.0% |
| Q1 2023 | $5,255,231 | +76.3% | 79,673 | +38.2% | 0.00% | +100.0% |
| Q4 2022 | $2,981,000 | -22.8% | 57,640 | +1.9% | 0.00% | 0.0% |
| Q3 2022 | $3,862,000 | -52.2% | 56,541 | -68.4% | 0.00% | -66.7% |
| Q2 2022 | $8,082,000 | -6.2% | 178,704 | +5.4% | 0.00% | 0.0% |
| Q1 2022 | $8,619,000 | +9.4% | 169,621 | +1.8% | 0.00% | +50.0% |
| Q4 2021 | $7,881,000 | +17.9% | 166,688 | -17.8% | 0.00% | 0.0% |
| Q3 2021 | $6,684,000 | -21.2% | 202,712 | +51.1% | 0.00% | -33.3% |
| Q2 2021 | $8,480,000 | +1339.7% | 134,157 | +598.7% | 0.00% | – |
| Q4 2019 | $589,000 | +19.2% | 19,200 | -6.3% | 0.00% | – |
| Q3 2019 | $494,000 | -77.9% | 20,500 | -76.7% | 0.00% | -100.0% |
| Q2 2019 | $2,234,000 | +138.4% | 88,170 | +83.5% | 0.00% | – |
| Q1 2019 | $937,000 | – | 48,058 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| AJU IB Investment Co., Ltd. | 1,114,962 | $63,776,000 | 24.13% |
| Octagon Capital Advisors LP | 548,374 | $31,367,000 | 10.87% |
| Ghost Tree Capital, LLC | 325,000 | $18,590,000 | 4.14% |
| Burrage Capital Management LLC | 81,357 | $4,654,000 | 3.55% |
| Aufman Associates Inc | 53,642 | $3,068,000 | 2.75% |
| ACUTA CAPITAL PARTNERS, LLC | 167,054 | $9,555,000 | 2.60% |
| Cormorant Asset Management, LP | 1,866,108 | $106,741,000 | 2.54% |
| Tri Locum Partners LP | 121,409 | $6,945,000 | 2.52% |
| venBio Partners LLC | 490,471 | $28,055,000 | 2.48% |
| HHLR ADVISORS, LTD. | 5,028,289 | $287,618,000 | 2.29% |